AbbVie (ABBV) Cash from Financing Activities (2012 - 2026)

AbbVie has disclosed Cash from Financing Activities across 15 years of filings, most recently posting $919.0 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 173.05% year-over-year to $919.0 million; the TTM figure through Mar 2026 stood at -$10.5 billion (up 38.99% YoY), while the FY2025 annual figure was -$12.7 billion, down 144.18% from the prior year.
• Cash from Financing Activities grew to $919.0 million in Q1 2026, from -$4.2 billion in the prior quarter.
• Over the last five years, Cash from Financing Activities for ABBV reached as high as $10.8 billion in Q1 2024 and fell as low as -$9.6 billion in Q4 2022.
• The 5-year median for Cash from Financing Activities is -$4.2 billion (2025), against an average of -$3.5 billion.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 119.66% — and 2024, when it jumped 274.73%.
• A 5-year view of Cash from Financing Activities shows it stood at -$9.6 billion in 2022, then soared by 53.82% to -$4.4 billion in 2023, then sank by 54.21% to -$6.9 billion in 2024, then soared by 39.28% to -$4.2 billion in 2025, then jumped by 122.06% to $919.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $919.0 million, -$4.2 billion, and -$4.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.